- Conditions
- Myofascial Pain
- Interventions
- Ketorolac, Lidocaine, Dexamethasone
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 2,102
matching trials from the live ClinicalTrials.gov search.
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
- Interventions
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2026
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 115 more
- Conditions
- Ocular Disease Requiring Surgery
- Interventions
- DEXTENZA®
- Drug
- Lead sponsor
- Nathan Steinle
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 3
- States / cities
- Paso Robles, California • San Luis Obispo, California • Santa Maria, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Leukemia, Lymphoma
- Interventions
- filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 22 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Ozurdex, Eylea
- Drug
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, leucovorin calcium, lonafarnib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Solid Tumors
- Interventions
- linsitinib, erlotinib, paclitaxel, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
- Conditions
- Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, etoposide, leucovorin calcium, mercaptopurine, methotrexate, prednisone, therapeutic hydrocortisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2012
- U.S. locations
- 128
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 114 more
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Squamous Cell Carcinoma of the Esophagus, Stage IA Esophageal Cancer, Stage IA Gastric Cancer, Stage IB Esophageal Cancer, Stage IB Gastric Cancer, Stage IIA Esophageal Cancer, Stage IIA Gastric Cancer, Stage IIB Esophageal Cancer, Stage IIB Gastric Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer
- Interventions
- bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Nephrolithiasis
- Interventions
- Genetic testing
- Diagnostic Test
- Lead sponsor
- Ryan L Steinberg
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Neural Tube Defects, Contraception, Oral Contraceptives (OC)
- Interventions
- Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
- Conditions
- Hypercholesterolemia
- Interventions
- Fish Oil, Cinnamon, Garlique,Turmeric, Plant Sterol, Red Yeast Rice, Rosuvastatin, Placebo
- Dietary Supplement · Drug · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- AL Amyloidosis
- Interventions
- Bortezomib, Cyclophosphamide, Dexamethasone, Isatuximab
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Orange, California • Atlanta, Georgia • Detroit, Michigan + 2 more
- Conditions
- Healthy Participants
- Interventions
- Midazolam, GDC-0853, Midazolam and GDC-0853, Rosuvastatin, Rosuvastatin and GDC-0853, Simvastatin, Simvastatin and GDC-0853, Itraconazole, GDC-0853 and itraconazole
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Madison, Wisconsin
- Conditions
- Subarachnoid Hemorrhage, Hypertension
- Interventions
- Clevidipine butyrate injectable emulsion
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
- Procedure · Drug · Other + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
- Interventions
- Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertension
- Interventions
- Amlodipine Besylate, Metoprolol Succinate
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Lumbar Puncture, Methotrexate
- Procedure · Drug · Biological
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
- Conditions
- Foot Ulcer, Diabetic
- Interventions
- Wound Dressing
- Device
- Lead sponsor
- Solventum US LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Montgomery, Alabama • Castro Valley, California • Bay Pines, Florida + 3 more
- Conditions
- Hydration
- Interventions
- Nuun electrolyte tablet, water
- Dietary Supplement · Other
- Lead sponsor
- University of Memphis
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Diabetic Macular Edema
- Interventions
- Bevacizumab, dexamethasone intravitreal implant
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana